WO2001083798A1 - Bacterial strains and fermentation processes for the production of 2-keto-l-gulonic acid - Google Patents
Bacterial strains and fermentation processes for the production of 2-keto-l-gulonic acid Download PDFInfo
- Publication number
- WO2001083798A1 WO2001083798A1 PCT/US2000/012037 US0012037W WO0183798A1 WO 2001083798 A1 WO2001083798 A1 WO 2001083798A1 US 0012037 W US0012037 W US 0012037W WO 0183798 A1 WO0183798 A1 WO 0183798A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- strain
- nrrl
- process according
- culture
- microorganism
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 29
- VBUYCZFBVCCYFD-NUNKFHFFSA-N 2-dehydro-L-idonic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C(=O)C(O)=O VBUYCZFBVCCYFD-NUNKFHFFSA-N 0.000 title claims abstract description 12
- VBUYCZFBVCCYFD-UHFFFAOYSA-N D-arabino-2-Hexulosonic acid Natural products OCC(O)C(O)C(O)C(=O)C(O)=O VBUYCZFBVCCYFD-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 230000001580 bacterial effect Effects 0.000 title abstract description 21
- 238000000855 fermentation Methods 0.000 title description 46
- 230000004151 fermentation Effects 0.000 title description 46
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 63
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 57
- 229960002920 sorbitol Drugs 0.000 claims abstract description 57
- 239000013598 vector Substances 0.000 claims abstract description 24
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 4
- 241000589236 Gluconobacter Species 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 96
- 244000005700 microbiome Species 0.000 claims description 87
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 claims description 57
- 230000008569 process Effects 0.000 claims description 55
- 235000010469 Glycine max Nutrition 0.000 claims description 40
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 239000000047 product Substances 0.000 claims description 18
- 241000589232 Gluconobacter oxydans Species 0.000 claims description 15
- 244000068988 Glycine max Species 0.000 claims description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 8
- 241000193755 Bacillus cereus Species 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 6
- 241000589516 Pseudomonas Species 0.000 claims description 6
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 5
- 229930027917 kanamycin Natural products 0.000 claims description 5
- 229960000318 kanamycin Drugs 0.000 claims description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 5
- 229930182823 kanamycin A Natural products 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 239000005862 Whey Substances 0.000 claims description 4
- 108010046377 Whey Proteins Proteins 0.000 claims description 4
- 102000007544 Whey Proteins Human genes 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 229960005322 streptomycin Drugs 0.000 claims description 4
- 241000589220 Acetobacter Species 0.000 claims description 3
- 108010073771 Soybean Proteins Proteins 0.000 claims description 3
- 239000004098 Tetracycline Substances 0.000 claims description 3
- 229960000723 ampicillin Drugs 0.000 claims description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 3
- 229960005091 chloramphenicol Drugs 0.000 claims description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 3
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 claims description 3
- 229960003276 erythromycin Drugs 0.000 claims description 3
- 235000013312 flour Nutrition 0.000 claims description 3
- 239000002054 inoculum Substances 0.000 claims description 3
- 235000013379 molasses Nutrition 0.000 claims description 3
- 229940001941 soy protein Drugs 0.000 claims description 3
- 229960000268 spectinomycin Drugs 0.000 claims description 3
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 claims description 3
- 229960002180 tetracycline Drugs 0.000 claims description 3
- 229930101283 tetracycline Natural products 0.000 claims description 3
- 235000019364 tetracycline Nutrition 0.000 claims description 3
- 150000003522 tetracyclines Chemical class 0.000 claims description 3
- 241000186146 Brevibacterium Species 0.000 claims description 2
- 241000588923 Citrobacter Species 0.000 claims description 2
- 241000186216 Corynebacterium Species 0.000 claims description 2
- 241000588914 Enterobacter Species 0.000 claims description 2
- 241000588698 Erwinia Species 0.000 claims description 2
- 241001467578 Microbacterium Species 0.000 claims description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 2
- 241000589634 Xanthomonas Species 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 108091008146 restriction endonucleases Proteins 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 7
- 241000320427 Ketogulonicigenium Species 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 60
- 210000004027 cell Anatomy 0.000 description 26
- 239000007787 solid Substances 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 17
- 239000000872 buffer Substances 0.000 description 13
- 229920001817 Agar Polymers 0.000 description 12
- 239000008272 agar Substances 0.000 description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 240000008042 Zea mays Species 0.000 description 9
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 9
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 9
- 235000005822 corn Nutrition 0.000 description 9
- 239000012620 biological material Substances 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 241000364057 Peoria Species 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 238000002703 mutagenesis Methods 0.000 description 7
- 231100000350 mutagenesis Toxicity 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000005273 aeration Methods 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 229940041514 candida albicans extract Drugs 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000012138 yeast extract Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 241000320433 Ketogulonicigenium robustum Species 0.000 description 5
- 239000002518 antifoaming agent Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 240000001817 Cereus hexagonus Species 0.000 description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000012262 fermentative production Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000004899 motility Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000011218 seed culture Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 101100371857 Caenorhabditis elegans unc-71 gene Proteins 0.000 description 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 3
- 239000007836 KH2PO4 Substances 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 235000010633 broth Nutrition 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 3
- 239000000920 calcium hydroxide Substances 0.000 description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- BJHIKXHVCXFQLS-OTWZMJIISA-N keto-L-sorbose Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-OTWZMJIISA-N 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- -1 rare earth salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 235000019157 thiamine Nutrition 0.000 description 3
- 229960003495 thiamine Drugs 0.000 description 3
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 3
- 239000011721 thiamine Substances 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- RXMWXENJQAINCC-DMTCNVIQSA-N 2,5-didehydro-D-gluconic acid Chemical compound OCC(=O)[C@@H](O)[C@H](O)C(=O)C(O)=O RXMWXENJQAINCC-DMTCNVIQSA-N 0.000 description 2
- RXMWXENJQAINCC-UHFFFAOYSA-N 2,5-diketo-D-gluconic acid Natural products OCC(=O)C(O)C(O)C(=O)C(O)=O RXMWXENJQAINCC-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- IZSRJDGCGRAUAR-MROZADKFSA-N 5-dehydro-D-gluconic acid Chemical compound OCC(=O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IZSRJDGCGRAUAR-MROZADKFSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000194107 Bacillus megaterium Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241001660259 Cereus <cactus> Species 0.000 description 2
- 241000186226 Corynebacterium glutamicum Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- RGHNJXZEOKUKBD-SKNVOMKLSA-N L-idonic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SKNVOMKLSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000927543 Pseudogluconobacter Species 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 241000831652 Salinivibrio sharmensis Species 0.000 description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 239000011575 calcium Chemical class 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000001822 immobilized cell Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011734 sodium Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000011426 transformation method Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- HMVYERAUBSAVAX-UHFFFAOYSA-N 1-nitro-1-nitrosoguanidine Chemical compound NC(=N)N(N=O)[N+]([O-])=O HMVYERAUBSAVAX-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- VBUYCZFBVCCYFD-JJYYJPOSSA-N 2-dehydro-D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)C(O)=O VBUYCZFBVCCYFD-JJYYJPOSSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 244000177578 Bacterium linens Species 0.000 description 1
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000186031 Corynebacteriaceae Species 0.000 description 1
- 241000186145 Corynebacterium ammoniagenes Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- DCNMIDLYWOTSGK-SRQIZXRXSA-N D-xylo-hexos-2-ulose Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C(=O)C=O DCNMIDLYWOTSGK-SRQIZXRXSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- VWWQXMAJTJZDQX-UHFFFAOYSA-N Flavine adenine dinucleotide Natural products C1=NC2=C(N)N=CN=C2N1C(C(O)C1O)OC1COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UHFFFAOYSA-N 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001468202 Microbacterium liquefaciens Species 0.000 description 1
- 241000983412 Microbacterium saperdae Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- GBDLMECRPIKBSW-IJIOZTSFSA-N OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)C(=O)CO Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)C(=O)CO GBDLMECRPIKBSW-IJIOZTSFSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 241000319304 [Brevibacterium] flavum Species 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940098164 augmentin Drugs 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229960005229 ceftiofur Drugs 0.000 description 1
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000005837 enolization reaction Methods 0.000 description 1
- 229960000740 enrofloxacin Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 229960003760 florfenicol Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000007273 lactonization reaction Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical class [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000006327 marine agar Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000009343 monoculture Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940071440 soy protein isolate Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- MUUHXGOJWVMBDY-UHFFFAOYSA-L tetrazolium blue Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 MUUHXGOJWVMBDY-UHFFFAOYSA-L 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- 229960000223 tilmicosin Drugs 0.000 description 1
- JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- ZJSAHDQVNRJQGU-UHFFFAOYSA-N urea;nitrate Chemical compound NC(N)=O.[O-][N+]([O-])=O ZJSAHDQVNRJQGU-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/58—Aldonic, ketoaldonic or saccharic acids
- C12P7/60—2-Ketogulonic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Definitions
- the present invention relates to the fields of microbiology and fermentation technology.
- the present invention further relates to the use of novel bacterial strains, ingredients and processes useful for the fermentative production of 2-keto-L-gulonic acid from D-sorbitol.
- 2-Keto-L-gulonic acid (“2-KLG”) is a significant intermediate in the preparation of L-ascorbic acid (vitamin C), an essential nutrient. 2-KLG has been synthesized in the past on an industrial scale using the Reichstein method (Helvetica ChimicaActa 77:311 (1934)). This method, however, has a number of disadvantages for commercial application, including the use of large quantities of solvents and the involvement of a number of complex reaction steps.
- U.S. Patent No. 2,421,611 discloses a method involving microbial oxidation of D-glucose to 5-keto-D-gluconic acid, followed by chemical or microbial reduction to L-idonic acid and subsequent microbial oxidation to 2-KLG.
- U.S. Patent No. 3,998,697 discloses a similar process involving the microbial oxidation of D-glucose to 2,5-diketo-D-gluconic acid, followed by microbial reduction to 2-KLG.
- Pseudomonas such as Pseudomonas sorbosoxidans
- mixtures of microorganisms from these and other genera such as Acetobacter, Bacillus, Serratia, Mycobacterium, and Streptomyces (U.S. Patent Nos. 3,912,592; 3,907,639; and 3,234,105).
- 2-KLG can be produced from D-sorbitol with the aid of microorganisms of the genera Acetobacter, Bacterium or Pseudomonas which are capable of oxidizing D-sorbitol under aerobic conditions producing 2-KLG.
- the yield of 2-KLG is low.
- D-sorbitol as a starting material would be preferable to L-sorbose because it is less expensive. However, L-sorbose is more efficiently converted to 2-KLG.
- a process that uses D-sorbitol as a starting material but provides L-sorbose for conversion combines the availability of D-sorbitol with the higher yield provided by L-sorbose. If part of the process is the conversion of D-sorbitol to L-sorbose, which is then converted to 2-KLG, then efficient production can be attained.
- the present invention provides microorganism strains and processes which efficiently produce 2-KLG from D-sorbitol via L-sorbose in a mixed culture.
- the invention provides a simpler and shorter fermentation with lower cost and higher yield for the production of 2-KLG from D-sorbitol versus the conventional method using two stage fermentation.
- a further embodiment of the present invention is directed to strains for the production of 2-KLG in cooperation with helper strains.
- Another embodiment of the present invention provides a process for the production of 2-KLG in which the fermentation medium contains soybean products.
- An additional embodiment of the present invention is to provide the bacterial strains of the present invention transformed by a vector, and a method for the transformation of the bacterial strains by a vector.
- the present invention which, in a first embodiment, is directed to a culture of a microorganism strain having the identifying characteristics of any of the microorganism strains NRRL
- Figure 1 is a depiction of the single stage fermentation modified to employ three organisms and soluble soy isolates ADM Soy Soluble and ADM RO Concentrate.
- FIG. 2 is a depiction of the RiboPrint® patterns of bacterial strains capable of producing L-sorbose from D-sorbitol. RiboPrint® patterns were obtained from G. oxydans strain NRRL B-30266 (ADM 205-95) and G. oxydans strain ATCC 621.
- FIG 3 is a depiction of the RiboPrint® patterns of bacterial strains capable of producing 2-KLG from L-sorbose.
- RiboPrint® patterns were obtained from the following bacterial strains: NRRL B-21627 (ADM X6L); NRRL B-21630 (ADM 86-96); and NRRL B-30265 (ADM 178-49).
- FIG. 4 is a depiction of the RiboPrint® patterns of helper bacterial strains. RiboPrint® patterns were obtained from B. ceret ⁇ sstrainNRRLB-30268
- ADM 1A9 and NRRL B-30267 (ADM C12B).
- the present invention is directed to a biologically pure culture of a microorganism strain comprising the identifying characteristics of a strain selected from the group consisting of NRRL B-30266, NRRL B-30265,
- the microorganism strains of the present embodiment are capable of producing 2-KLG from D-sorbitol by fermentation in mixed culture.
- the mixed culture comprises at least two different microorganism strains which are capable of producing at least about 40 g/L of 2-KLG from D-sorbitol, more preferably at least about 60 g/L, and most preferably at least about 80 g/L.
- the present invention is directed to a process for the production of 2-KLG utilizing the inventive microorganism strains.
- the process (which as used herein, is synonymous with method) comprises culturing a microorganism strain comprising the identifying characteristics of NRRL B- 30265 or a mutant thereof in mixed culture with a microorganism strain capable of converting D-sorbitol to L-sorbose, in a medium containing D-sorbitol, for a time sufficient for said D-sorbitol to be converted to 2-KLG and recovering the 2-KLG.
- the inventive fermentation process comprises cultivating the microorganisms in a synthetic or natural culture medium for a sufficient time and then isolating the accumulated 2-KLG from the culture medium and/or cells of the microorganisms.
- the mixed culture comprises at least one microorganism strain that is capable of producing L- sorbose from D-sorbitol.
- Any microorganism or mixture of microorganisms that can convert D-sorbitol to L-sorbose in the presence of the 2-KLG producing strain(s) or a mutant or variant thereof while not adversely affecting its ability to convert L-sorbose to 2-KLG can be employed.
- the microorganism employed is a strain of Gluconobacter oxydans, more preferably G oxydans strain ATCC 621 or G. oxydans strain IFO 3293 or mutants thereof.
- the mutant is selected from media containing more than 100 g/L or preferably more than 150 g/L of L-sorbose. More preferably, the L-sorbose producing microorganism is strain NRRL B-30266 (ADM strain 205-95), a mutant derived from G. oxydans strain ATCC 621.
- RiboPrint® is an automated ribotyping system that generates and analyzes genetic fingerprints of bacteria.
- the genetic fingerprinting patterns are normalized digital representations of the genetic data for each sample.
- the patterns obtained by this method are useful for differentiating not only between organisms of different species, but also between different strains of the same species.
- RiboPrint® patterns obtained for strain NRRL B-30266 (ADM strain 205-95) and a comparative strain known to be capable of producing L-sorbose from D-sorbitol are depicted in Figure 2.
- mutants and variants thereof can also be employed in the inventive process, provided that these mutants and variants are also capable of converting D-sorbitol to L-sorbose in the presence of the 2-KLG producing strain(s) or a mutant or variant thereof while not adversely affecting its ability to convert L-sorbose to 2-KLG.
- a "biologically pure" strain is intended to mean the strain separated from materials with which it is normally associated in nature. Note that a strain associated with other strains, or with compounds or materials that it is not normally found with in nature, is still defined as “biologically pure.” A monoculture of a particular strain is, of course, “biologically pure. "
- the D-sorbitol starting material can be present in the medium prior to introduction of one or more of the microorganisms or can be added to the medium after introduction of one or more of the microorganisms, either all at once at the beginning or continuously or in installments over the course of cultivation.
- the mixed culture further comprises at least one microorganism strain that is capable of producing 2-KLG from L-sorbose.
- strain NRRL B-30265 (ADM 178-49) include, but are not limited to: (1) Cell Morphology— gram-negative; can be gram variable in older cultures; pleiomorphic; short rods or coccobacilli; cells appear singly and in pairs; can form short chains or filaments; does not form spores;
- Colony Morphology punctiform, convex, entire, smooth, butyrous and translucent; beige or light brown coloration in older colonies on some media;
- Motility no motility observed in wet mounts prepared from liquid cultures or 2% agar plate cultures; motility observed by stabbing fresh culture into a plate of BUGMTM medium (available from Biolog, Inc., Cat. # 70001) that has been partially solidified using 0.3%to 0.4% agar; cells manufacture flagella under conditions used to observe motility;
- RiboPrint® patterns obtained for strain NRRL B-30265 (ADM 178-49) and a number of comparative strains known to be capable of producing 2-KLG from L-sorbose are depicted in Figure 3.
- mutants and variants thereof can also be employed in the inventive process, provided that these mutants and variants are also capable of producing at least about 40 g/L of 2-KLG from D-sorbitol in mixed culture.
- a mutant of a given strain of the present invention is derived from one of the strains of the present invention, namely, NRRL B-30266 (ADM 205-95), NRRL B-30265 (ADM 178-49), NRRL B-30267 (ADM C12B) or microorganism strain NRRL B-30268 (ADM 1 A9).
- a mutant may or may not have the same identifying biological characteristics of the parent or progenitor strain, as long as the mutant aids in the fermentative production of 2-KLG.
- Illustrative examples of suitable methods for preparing mutants and variants of the inventive microorganism strains include, but are not limited to: mutagenesis by irradiation with ultraviolet light or X-rays, or by treatment with a c h e m i c a l m u t a g e n s u c h a s n i t r o s o g u an i d i n e (N-methyl-N'-nitro-N-nitrosoguanidine), methylmethanesulfonate, nitrogen mustard and the like; gene integration techniques, such as those mediated by insertional elements or transposons or by homologous recombination of transforming linear or circular DNA molecules; and transduction mediated by bacteriophages such as PI. These methods are well known in the art and are described, for example, in J. H. Miller, Experiments in Molecular Genetics, Cold
- Mutated strains derived from the inventive microorganism strains using known methods are then preferably selected or screened for improved 2-KLG production potential or for other desirable properties related to their utility in producing 2-KLG from D-sorbitol.
- mutagenized cells are selected on the basis of their resistance to growth-inhibitory concentrations of partially derivatized or degraded 2-KLG, such as 2-KLG derivatives generated by autoclaving or other exposure to heat.
- the selective agent can be generated by other means of chemical modification of 2-KLG, including, but not limited to: ammo-substitution to create 2-amino-L-gulonic acid or 2-amino-L-idonic acid; oxidation at the C 6 position to create 5-keto-glucaric acid; modifications leading to various thiol- or deoxy-derivatives or various unsaturated derivatives of 2-KLG; or by any other means that will be clear to individuals versed in the art.
- any period of time sufficient to produce 2-KLG in the culture medium can be used, and the instant process can be conducted by means of a variety of methods.
- Both microorganisms can be simultaneously inoculated in the medium at the initiation of cultivation.
- the L-sorbose-producing strain can be inoculated first and 2-KLG-producing strain subsequently inoculated after a period of cultivation.
- Both microorganisms can be inoculated separately into respective media, and then one is added to the other or vice versa either portionwise or continuously after a period of cultivation, followed by another period of cultivation.
- the ratio of the amount of the 2-KLG-producing strain relative to the amount of the L-sorbose-producing strain is in the range of from about 10:1 to about 1:10, more preferably from about 5:1 to about 1:5.
- any suitable culturing method can be employed for the microorganisms used.
- the method of mixing can be determined in compliance with the properties of the specific microorganism to be employed.
- the incubation times, inoculation schedules and ratios of the microorganisms can be optimized for the specific microorganism employed.
- the ratio of the amount of the L-sorbose-producing microorganism to the 2-KLG-producing microorganism and the times of inoculations are preferably selected and determined in view of the growth rate of the respective microorganisms, the L-sorbose producing ability and the ability for converting L-sorbose into 2-KLG of the microorganisms involved, and in view of the properties of the media to be used.
- products obtained by treating the cells can also be used as a substitute for either one of the growing cells.
- Any products resulting from treating the cells of the inventive microorganisms for instance, resting cells, lyophilized cells or immobilized cells, can be employed.
- the L-sorbose and 2-KLG-producing microorganisms can be inoculated with and cultivated in a medium which includes D-sorbitol.
- the microorganism strains are cultivated in a natural or synthetic medium containing D-sorbitol for a sufficient period of time for 2-KLG to be produced, and the accumulated 2-KLG is subsequently isolated.
- a preparation derived from the cells of the microorganism strains can be contacted with D-sorbitol for a sufficient time and the accumulated 2-KLG can then be isolated.
- a preparation derived from the cells is intended to mean any and all extracts of cells from the culture broths of the inventive strain or a mutant or variant thereof, acetone dried cells, immobilized cells on or within supports, such as polyacrylamide gel, K-carrageenan, calcium alginate and the like, and similar preparations. Any technique and/or method for the cultivation of microorganisms can be adopted. Cultivation of the inventive microorganism strain can be accomplished using any of the submerged fermentation techniques known to those skilled in the art, such as airlift, traditional sparged-agitated designs, or in shaking culture. The use of aerated and agitated submerged fermentors is particularly preferred.
- the medium used herein can be solid or liquid, synthetic (i. e. man-made) or natural, and contains sufficient nutrients for the cultivation of the inventive microorganism strains.
- the medium employed is a liquid medium, more preferably a synthetic liquid medium.
- the starting material, D-sorbitol can be present in the medium prior to introduction of the inventive microorganism strains or can be added to the medium after introduction of the strains, either all at once at the beginning or continuously or in installments over the course of cultivation, or can be generated in situ by fermentative conversion.
- the amount of D-sorbitol employed can be determined empirically by one skilled in the art, but is at least sufficient for the microorganism strains to produce at least about 40 g/L of 2-KLG. In this instant process, a concentration of D-sorbitol of about 20 to about 250 g/L in total is generally used and, in particular, a concentration of about 50 to about 200 g/L in total.
- the natural or synthetic culture medium also contains a nitrogen source, suitable inorganic salts, and, as appropriate, various trace nutrients, growth factors and the like suitable for cultivation of the microorganism strain, and can also contain at least one supplementary carbon source.
- the amount of each of these additional ingredients to be employed is preferably selected to maximize 2-KLG production. Such amounts can be determined empirically by one skilled in the art according to the various methods and techniques known in the art.
- these additional ingredients can be added to the medium before the start of culturing, step-by-step or continuously during culturing.
- the culture medium contains soybean products to supplement nutrients for the mixed cultures.
- the soybean products are from the processing of soybeans to produce soy oil, soy proteins and other products.
- alcohol washed soluble isolates are products from the stream of alcohol washed concentration of defatted soy flakes.
- ADM Soy Soluble containing about 5-15% dry solid is the first product from this process. It contains about 4- 10% protein, about 8-16% fat, about 30-60% sucrose, about 15-25% stachyose, about 3-9% raffinose and about 5-12% ash.
- the water washed soluble isolates are products from the water processing of soy protein isolate using defatted soy flakes.
- ADM RO Concentrate containing about 2-6% dry solid is a product from this process. It contains about 13-21% protein, about 2-6% fat, about 18-28% sucrose, about 6-13% stachyose, about 1- 5% raffinose, about 13-21% pentose and about 20-35% ash.
- the soybean products in the media comprise soy flour, soy protein and its hydrolysate, soy peptone, soy isolates, soluble soy isolates, soy whey or soy molasses. More preferably, the soybean products comprise soluble soy isolates or soy whey.
- Suitable supplemental carbon sources include, but are not limited to : other carbohydrates, such as glucose, fructose, mai nitol, starch or starch hydrolysate, cellulose hydrolysate and molasses; organic acids, such as acetic acid, propionic acid, lactic acid, formic acid, malic acid, citric acid, and fumaric acid; and alcohols, such as glycerol, inositol, mannitol and sorbitol.
- other carbohydrates such as glucose, fructose, mai nitol, starch or starch hydrolysate, cellulose hydrolysate and molasses
- organic acids such as acetic acid, propionic acid, lactic acid, formic acid, malic acid, citric acid, and fumaric acid
- alcohols such as glycerol, inositol, mannitol and sorbitol.
- suitable nitrogen sources include, but are not limited to : ammonia, including ammonia gas and aqueous ammonia; ammonium salts of inorganic or organic acids, such as ammonium chloride, ammonium nitrate, ammonium phosphate, ammonium sulfate and ammonium acetate; urea; nitrate or nitrite salts, and other nitrogen-containing materials, including amino acids as either pure or crude preparations, meat extract, peptone, fish meal, fish hydrolysate, corn steep liquor, casein hydrolysate, soybean cake hydrolysate, yeast extract, dried yeast, ethanol-yeast distillate, soybean flour, cottonseed meal, and the like.
- ammonia including ammonia gas and aqueous ammonia
- ammonium salts of inorganic or organic acids such as ammonium chloride, ammonium nitrate, ammonium phosphate, ammonium sulfate and ammonium acetate
- urea nit
- suitable inorganic salts include, but are not limited to: salts of potassium, calcium, sodium, magnesium, manganese, iron, cobalt, zinc, copper and other trace elements, and phosphoric acid.
- Illustrative examples of appropriate trace nutrients, growth factors, and the like include, but are not limited to: coenzyme A, pantothenic acid, pyridoxine- HC1, biotin, thiamine, riboflavin, flavine mononucleotide, flavine adenine dinucleotide, DL-6,8-thioctic acid, folic acid, Vitamin B 12 , other vitamins, amino acids such as cy steine and hydroxyproline, bases such as adenine, uracil, guanine, thymine and cytosine, sodium thiosulfate, p- or r-aminobenzoic acid, niacinamide, nitriloacetate, and the like, either as pure or partially purified chemical compounds or as present in natural materials.
- the main fermentation medium used for 2-KLG production contains about 1 OOg/L to about
- D-sorbitol from about 2 g/L to about 10 g/L dry solid of ADM Soy Soluble or ADM RO Concentrate, from about 10 g/L to about 30 g/L dry solid of corn steep liquor, and from about 0.2 ml/L to about 0.4 ml/L antifoam, with pH. from about 6.0 to about 7.0.
- the culture conditions employed including temperature, pH, aeration rate, agitation rate, culture duration, and the like, can be determined empirically by one of skill in the art to maximize 2-KLG production. The selection of specific culture conditions depends upon factors such as the particular inventive microorganism strain employed, medium composition and type, culture technique, and similar considerations.
- cultivation takes place at a temperature in the range of 0°C to 40 °C, preferably 5 °C to 36 °C, and even more preferably 20 °C to 34° C and at a pH in the range of 5.0 to 9.0, preferably in the range of 5.5 to 8.5, more preferably about 6.0 to 8.0.
- the culture conditions employed can, of course, be varied by known methods at different timepoints during cultivation, as appropriate, to maximize 2-KLG production.
- 2-KLG is accumulated in the cells and/or culture medium.
- any suitable acidic or basic agent can be added to the medium in a suitable amount at a suitable time during the cultivation.
- the same object can alternatively be accomplished by incorporating a suitable buffer or buffering agent into the medium at the beginning of the cultivation.
- pH can be controlled using NH 4 OH, Ca(OH) 2 or CaCO 3 .
- the 2-KLG that has accumulated in the cells and/or culture broth is isolated according to any of the known methods including ion exchange chromatography, gel filtration, solvent extraction, affinity chromatography, or any combination thereof.
- the microorganisms are first removed from the culture broth by known methods, such as centrifugation or filtration, and the resulting solution concentrated in vacuo .
- Crystalline 2-KLG is then recovered by filtration and, if desired, purified by recrystallization.
- 2-KLG can be recovered using such known methods as the use of ion-exchange resins, solvent extraction, precipitation, salting out and the like.
- 2-KLG is recovered as a free acid, it can be converted to a salt, as desired, with sodium, potassium, calcium, ammonium or similar cations using conventional methods.
- 2-KLG when 2-KLG is recovered as a salt, it can be converted to its free form or to a different salt using conventional methods.
- the 2-KLG or its salt thus obtained can be used directly for conversion to L-ascorbic acid by esterif ⁇ cation, followed by enolization and lactonization. Further, the 2-KLG can be converted to any conventional salt of ascorbic acid.
- the mixed culture comprises an additional microorganism strain which is capable of providing helper function.
- helper strain is intended to mean a strain ofa microorganism that increases the amount of 2-KLG produced in the inventive process.
- Suitable helper strains can be determined empirically by one skilled in the art.
- suitable helper strains include, but are not limited to, members of the following genera: Aureobacterium (preferably A. liquefaciens or A.
- Corynebacterium preferably C. ammoniagenes or C. glutamicum
- Bacillus preferably B. linens or B. flavum
- Pseudomonas Proteus, Enterobacter, Citrobacter, Erwinia, Xanthomonas and Flavobacterium .
- the helper microorganism strain is Bacillus cereus, more preferably the spore-forming B. cereus strain NRRL B-30267 (ADM C12B) or its mutant thereof.
- mutants of B. cereus strain NRRL B-30267 are selected to be incapable of producing spores.
- the non-spore forming mutant strain NRRL B-30268 (ADM 1A9) is used in the inventive process. Strains ADM C12B and ADM 1A9 were deposited at the Agricultural
- NRRL Research Service Culture Collection
- ADM C12B strain NRRL B-30267
- ADM 1A9 strain NRRL B- 30268, respectively.
- the helper strain is preferably incubated in an appropriate medium under suitable conditions for a sufficient amount of time until a culture of sufficient population is obtained.
- This helper strain inoculum can then be introduced into the culture medium for production of 2-KLG either separately or in combination with the inventive microorganism strains, i. e. , a mixed inoculum.
- the ratio of the amount of the helper strain relative to the amount of strain NRRL B- 30265 (ADM 178-49) is in the range of from about 10:1 to about 1:10,000.
- a further embodiment of the present invention provides a mixed microorganism culture which can be used in the inventive process.
- a preferred mixed microorganism culture according to the instant invention comprises a mixture formed from a biologically pure culture ofa microorganism strain having the identifying characteristics of strain NRRL B-30266 and a biologically pure culture of a microorganism strain having the identifying characteristics of strain NRRL B-30265.
- the mixed microorganism culture of the present invention is characterized by the ability to produce 2-KLG from D-sorbitol in a yield of at least about 40 g/L, preferably at least 60 g/L, more preferably at least 80 g/L.
- the mixed culture can further comprise an additional microorganism strain which is capable of providing helper function.
- the present invention also relates to the strains of the present invention transformed with vectors which optionally include at least one marker gene.
- Recombinant constructs can be introduced into the bacterial strains of the present invention using well known techniques such as transduction, transfection, conjugation, and electroporation or other transformation methods.
- the vector can be, for example, a phage, plasmid, cosmid or a minichromosome.
- host and “host cells” are synonymous with the cells of the microorganism strains of the present invention.
- Polynucleotides of interest can be joined to a vector containing a selectable marker for propagation in the host.
- a plasmid vector can be introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid.
- vectors comprising cis-acting control regions to a polynucleotide of interest.
- Appropriate trans-acting factors can be supplied by the host, supplied by a complementing vector, or supplied by the vector itself upon introduction into the host.
- the vectors provide for specific expression, which can be inducible, mutant-specific and/or condition- specific. Particularly preferred among such vectors are those inducible by environmental factors that are easy to manipulate, such as temperature, nutrient additives or chemical additives. Other suitable environmental factors will be readily apparent to the skilled artisan.
- Expression vectors useful in the present invention include chromosomal-, episomal- vectors, e.g. , vectors derived from plasmids, bacteriophage, and vectors derived from combinations thereof, such as cosmids and phagemids.
- a DNA insert of interest should be operatively linked to an appropriate promoter which is preferably ahost-derived promoter.
- the expression constructs will further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation.
- the coding portion of the mature transcripts expressed by the constructs will include a translation initiating codon appropriate for the host at the beginning and a termination codon appropriately positioned at the end of the polypeptide to be translated.
- the expression vectors will preferably include at least one marker capable of being selected or screened for.
- markers include amikacin, augmentin (amoxicillin plusclavulonic acid), ampicillin, cefazolin, cefoxitin, ceftazidime, ceftiofur, cephalothin, chloramphenicol, enrofloxacin, erythromycin, florfenicol, gentamicin, imipenem, kanamycin, penicillin, sarafloxicin, spectinomycin, streptomycin, tetracycline, ticarcillin, or tilmicosin resistance, genes.
- Preferred markers include ampicillin, chloramphenicol, erythromycin, kanamycin, penicillin, spectinomycin, streptomycin, and/or tetracycline. Other suitable markers will be readily apparent to the skilled artisan.
- a preferred vector is pMF 1014- ⁇ (M. T. Follettie, "DNA Technology for Corynebacterium glutamicum: Isolation and Characterization of Amino Acid Biosynthetic Genes," Ph.D. Dissertation, Massachusetts Institute of Technology, Cambridge, Massachusetts (1989)), which comprises the pSRl-o. replicon and a kanamycin resistance determinant.
- pMF1014- ⁇ comprises the pSRl replicon (Archer, J.A.
- Introduction of the construct into the host cell can be effected by calcium phosphate transfection, D ⁇ A ⁇ -dextran mediated transfection, cationic lipid- mediated transfection, electroporation and other transformation methods, transduction, infection or other methods.
- Such methods are described in many standard laboratory manuals, such as Davis et al. , "Basic Methods in Molecular
- TM buffer 10 mL was added to each tube, then the cells were pelleted by centrifugation, washed twice in TM buffer, then resuspended in 4.0 mL of 0.1 M NaH 2 PO 4 buffer (pH 7.2 adjusted with KOH). The washed cell suspensions were further diluted in phosphate buffer, and aliquots were spread on plates of PYM medium, TBC medium (Difco Trypton
- ADM 205-95 One loopful culture of ADM 205-95 was inoculated into 250ml baffled shaker flask containing SM7 seed medium (Quest N-Z SoyTM 10 g/L, D- sorbitol 10 g/L, D-mannitol 20 g/L, corn steep liquor 2 % dry solid, niacinamide 0.05 g/L, thiamine 0.3 g/L, pantothenic acid 0.4 g/L, j_ aminobenzoic acid 0.2 g/L, pH 6.7), and incubated at 30 °C and 240 rpm shaker for 22 hours.
- SM7 seed medium Quest N-Z SoyTM 10 g/L, D- sorbitol 10 g/L, D-mannitol 20 g/L, corn steep liquor 2 % dry solid, niacinamide 0.05 g/L, thiamine 0.3 g/L, pantothenic acid 0.4 g/L
- Mutants selected for the production of 2-KLG in this invention have been developed from mutants derived from K. robustum ADM-X6L (NRRL B-21627, U.S. Patent No.5,834,231).
- Strain ADM 171-109 amutant developed originally from ADM -X6L, has been improved for the production of 2-KLG, and showed a mild resistance to L-sorbose. This strain thereof was subjected to mutagenesis, and variants showing improvements on both 2-KLG production and L-sorbose resistance were recovered.
- Bacterial cultures were grown in PYM medium to mid-log phase, then pelleted by centrifugation and resuspended in 2 mL of TM buffer in a sterile tube.
- the 2 mL cell suspension was mixed with 60 ⁇ L of a 5.0 mg/mL solution of NTG, then incubated at 30° C for 30 minutes. After incubation, 10 mL of TM buffer was added to each tube, then the cells were pelleted by centrifugation, washed twice in TM buffer, then resuspended in 4.0 mL of 0.1 M NaH 2 PO 4 buffer.
- CM6 medium contained Difco Bacto SoytoneTM 10 g/L, D-sorbitol 5g/L, D-mannitol 10 g/L, malt extract 5 g/L, yeast extract 5 g/L, K 2 HPO 4 1 g/L,
- ADM 178-49 (NRRL B-30265) was inoculated into 250mL baffled shaker flask containing SM7 seed medium, and incubated at 30 °C and 240 rpm shaker for 22 hours. Two mL of seed contents were used to inoculate a baffled shaker flask containing 25 mL of fermentation medium FM10 and about 130 g/L of L-sorbose, and flasks were shaken for 72 hours at 30 °C and 240 rpm. Strain ADM 178-49 produced 62.6-67.8 g/L of 2-KLG with about 100 % of yield from L-sorbose in these tests.
- ADM C 12B (NRRL B-30267) is a spore forming bacteria which has been isolated from an ADM research site and identified to be Bacillus cereus. This strain has been found to have the helper function for 2-KLG production in this invention. To further improve the fermentation process and to prevent cross contamination, non-spore forming mutants, which are preferred for this invention, have since been developed from this strain.
- Strain B. cereus ADM C12B was grown in CM6 medium to mid-log phase, then pelleted by centrifugation and resuspended in 2 mL of TM buffer in a sterile tube. The 2 mL cell suspension was mixed with NTG at the final concentration of 50 g/mL, then incubated at 30°C for 30 minutes. After incubation, 10 mL of TM buffer was added to the tube. The cells were pelleted by centrifugation, washed twice in TM buffer, then resuspended in 4.0 mL of 0.1
- Colonies were then picked up and transferred to microplates containing PYM agar medium. Each well of microplate would contain only one isolate.
- mutants derived from both L-sorbose producing strains and 2-KLG producing strains were tested in the shaker flask.
- mutants derived from G oxydans ATCC 621, the L-sorbose producer were tested in the D- sorbitol medium with the mixed culture of T robustum ADM 178-49 (NRRL B- 30265), the 2-KLG producer.
- T robustum ADM 178-49 NRRL B- 30265
- Strain ADM 178-49 (NRRL B-30265) was cultured in a 500 mL baffled shaker flask containing 50 mL CM6 medium, and shaken at 30 °C, 240 rpm for 20 hours.
- Strain ATCC 621 was cultured separately in a 500 mL baffled shaker flask containing 50 mL PYM medium, and shaken at 30°C, 240 rpm for 20 hours.
- culture ADM 178-49 had OD 660nm at 1.1, and culture ATCC 621 at 3.9. Both cultures were mixed at different ratios (for example, at 3:1, 2:1, 1:1, 1:2, and 1 :3) and then stored at -72°C deep freezer.
- K. robustum ADM-X6L (NRRL-B-21627)
- helper strains B. cereus ADM C12B and its non-spore forming mutant ADM 1 A9 were used in this study.
- Frozen cultures of ADM 205-95, ADM 178-49, ADM C12B, and ADM 1 A9 in 1.5 mL vials were inoculated separately into 2 L baffled flasks containing 250 mL SM7A.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002408068A CA2408068A1 (en) | 2000-05-04 | 2000-05-04 | Bacterial strains and fermentation processes for the production of 2-keto-l-gulonic acid |
PCT/US2000/012037 WO2001083798A1 (en) | 2000-05-04 | 2000-05-04 | Bacterial strains and fermentation processes for the production of 2-keto-l-gulonic acid |
AU2000246957A AU2000246957C1 (en) | 2000-05-04 | 2000-05-04 | Bacterial Strains and Fermentation Processes for the Production of 2-Keto-L-Gulonic Acid |
EP00928775A EP1278879A1 (en) | 2000-05-04 | 2000-05-04 | Bacterial strains and fermentation processes for the production of 2-keto-l-gulonic acid |
AU4695700A AU4695700A (en) | 2000-05-04 | 2000-05-04 | Bacterial strains and fermentation processes for the production of 2-keto-l-gulonic acid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2000/012037 WO2001083798A1 (en) | 2000-05-04 | 2000-05-04 | Bacterial strains and fermentation processes for the production of 2-keto-l-gulonic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001083798A1 true WO2001083798A1 (en) | 2001-11-08 |
Family
ID=21741348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/012037 WO2001083798A1 (en) | 2000-05-04 | 2000-05-04 | Bacterial strains and fermentation processes for the production of 2-keto-l-gulonic acid |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1278879A1 (en) |
AU (2) | AU4695700A (en) |
CA (1) | CA2408068A1 (en) |
WO (1) | WO2001083798A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101629147B (en) * | 2009-06-30 | 2011-04-27 | 南京林业大学 | A kind of bacillus cereus and its application in promoting the growth of poplar |
WO2015135980A1 (en) * | 2014-03-11 | 2015-09-17 | Basf Se | The use of polymers to improve the rheology of base suspensions during fermentation |
EP3067426A3 (en) * | 2008-09-24 | 2016-12-07 | Sanofi Pasteur Biologics, LLC | Methods and compositions for increasing toxin production |
CN111893073A (en) * | 2020-08-14 | 2020-11-06 | 山东鲁维制药有限公司 | Method for promoting growth and acid production of ketogulonic acid bacteria |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101603060B (en) * | 2009-07-10 | 2011-06-01 | 天津大学 | Method for Improving the Production of 2-Keto-L-Gulonic Acid by Gluconobacter oxidans |
CN106636231A (en) * | 2016-12-26 | 2017-05-10 | 中国科学院沈阳应用生态研究所 | Method for improving production capacity of acid producing bacteria by adopting Vc two-step fermentation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0221707A2 (en) * | 1985-10-22 | 1987-05-13 | Takeda Chemical Industries, Ltd. | A method for producing 2-keto-L-gulonic acid |
WO1998017819A1 (en) * | 1996-10-24 | 1998-04-30 | Archer-Daniels-Midland Company | Novel bacterial strains and use thereof in fermentation processes for 2-keto-l-gulonic acid production |
-
2000
- 2000-05-04 CA CA002408068A patent/CA2408068A1/en not_active Abandoned
- 2000-05-04 EP EP00928775A patent/EP1278879A1/en not_active Withdrawn
- 2000-05-04 AU AU4695700A patent/AU4695700A/en active Pending
- 2000-05-04 WO PCT/US2000/012037 patent/WO2001083798A1/en not_active Application Discontinuation
- 2000-05-04 AU AU2000246957A patent/AU2000246957C1/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0221707A2 (en) * | 1985-10-22 | 1987-05-13 | Takeda Chemical Industries, Ltd. | A method for producing 2-keto-L-gulonic acid |
WO1998017819A1 (en) * | 1996-10-24 | 1998-04-30 | Archer-Daniels-Midland Company | Novel bacterial strains and use thereof in fermentation processes for 2-keto-l-gulonic acid production |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3067426A3 (en) * | 2008-09-24 | 2016-12-07 | Sanofi Pasteur Biologics, LLC | Methods and compositions for increasing toxin production |
CN101629147B (en) * | 2009-06-30 | 2011-04-27 | 南京林业大学 | A kind of bacillus cereus and its application in promoting the growth of poplar |
WO2015135980A1 (en) * | 2014-03-11 | 2015-09-17 | Basf Se | The use of polymers to improve the rheology of base suspensions during fermentation |
CN111893073A (en) * | 2020-08-14 | 2020-11-06 | 山东鲁维制药有限公司 | Method for promoting growth and acid production of ketogulonic acid bacteria |
Also Published As
Publication number | Publication date |
---|---|
AU2000246957C1 (en) | 2005-09-22 |
AU2000246957B2 (en) | 2005-04-14 |
EP1278879A1 (en) | 2003-01-29 |
AU4695700A (en) | 2001-11-12 |
CA2408068A1 (en) | 2001-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU717515B2 (en) | Novel bacterial strains and use thereof in fermentation processes for 2-keto-L-gulonic acid production | |
EP0518136B1 (en) | Fermentation process for producing 2-keto-L-gulonic acid | |
AU762825B2 (en) | Bacterial strains for the production of 2-keto-L-gulonic acid | |
KR100799796B1 (en) | Method for producing L-ascorbic acid and di-erythorbic acid by microorganisms | |
US6387654B1 (en) | Bacterial strains and fermentation processes for the production of 2-keto-l-gulonic acid | |
AU2000246957B2 (en) | Bacterial strains and fermentation processes for the production of 2-keto-l-gulonic acid | |
AU2000246957A1 (en) | Bacterial Strains and Fermentation Processes for the Production of 2-Keto-L-Gulonic Acid | |
JP3848297B2 (en) | Microorganism producing riboflavin and method for producing riboflavin using the same | |
JP3428078B2 (en) | Biotin production method and microorganism used | |
JP3926292B2 (en) | Microorganism producing riboflavin and method for producing riboflavin using the same | |
JPH0584067A (en) | Production of inosine by fermentation | |
MXPA01002475A (en) | Bacterial strains for the production of 2-keto-l-gulonic acid | |
WO2004029262A2 (en) | Production of 2 - keto - l - gulonic acd | |
MXPA99003710A (en) | Novel bacterial strains and use thereof in fermentation processes for 2-keto-l-gulonic acid production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2408068 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000246957 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000928775 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000928775 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000246957 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000928775 Country of ref document: EP |